Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: Kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1315-1321

  Ye, Zhi Wei ^a   Augustijns, Patrick ^a   Annaert, Pieter ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CHOLYLGLYCYLAMIDOFLUORESCEIN; DARUNAVIR; ESTRONE SULFATE; FLUORESCEIN; INDINAVIR; NELFINAVIR; ORGANIC ANION TRANSPORTER; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TAUROCHOLIC ACID; TRITIUM;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG UPTAKE; LIVER CELL CULTURE; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM DEPLETION; TEMPERATURE DEPENDENCE;

ANIMALS; BIOLOGICAL TRANSPORT; FLUORESCEINS; HEPATOCYTES; HIV PROTEASE INHIBITORS; KINETICS; MALE; RATS; RATS, WISTAR; TEMPERATURE;

HUMAN IMMUNODEFICIENCY VIRUS; RATTUS; VIR;

EID: 46449108452     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019398     Document Type: Article

References (31)

1. Annaert P, Swift B, Lee JK, and Brouwer KLR (2007) Drug transport in the liver, in Drug Transporters: Molecular Characterization and Role in Drug Disposition (You G and Morris M eds), John Wiley & Sons, Inc., New York.
2. Annaert PP, Turncliff RZ, Booth CL, Thakker DR, and Brouwer KL (2001) P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab Dispos 29:1277-1283.
3. + bile acid cotransport system in COS-7 cells. Am J Physiol 266:G382-387.
4. Bravo P, Bender V, and Cassio D (1998) Efficient in vitro vectorial transport of a fluorescent conjugated bile acid analogue by polarized hepatic hybrid WIF-B and WIF-B9 cells. Hepatology 27:576-583.
5. Bruno R, Sacchi P, Maiocchi L, Patruno S, and Filice G (2006) Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis 38:363-373.
6. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, and Stieger B (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86.
7. Funk C, Ponelle C, Scheuermann G, and Pantze M (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627-635.
8. Hoetelmans R, Van der Sandt I, Pauw MD, Struble K, Peeters M, and Van der Geest R (2003) TMC114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers., in 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Abstract 549; Boston, MA.
9. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, and Brouwer KL (2004) P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharmacol Res 21:1294-1302.
10. Holzinger F, Schteingart CD, Ton-Nu HT, Cerre C, Steinbach JH, Yeh HZ, and Hofmann AF (1998) Transport of fluorescent bile acids by the isolated perfused rat liver: kinetics, sequestration, and mobilization. Hepatology 28:510-520.
11. Holzinger F, Schteingart CD, Ton-Nu HT, Eming SA, Monte MJ, Hagey LR, and Hofmann AF (1997) Fluorescent bile acid derivatives: relationship between chemical structure and hepatic and intestinal transport in the rat. Hepatology 26:1263-1271.
12. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J, Zocharski P, Cai H, Sinclair JF, and Sahi J (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 76:220-228.
13. (+)/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J Pharmacol Exp Ther 292:505-511.
14. Liu X, Brouwer KL, Gan LS, Brouwer KR, Stieger B, Meier PJ, Audus KL, and LeCluyse EL (1998) Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharmacol Res 15:1533-1539.
15. Maglova LM, Jackson AM, Meng XJ, Carruth MW, Schteingart CD, Ton-Nu HT, Hofmann AF, and Weinman SA (1995) Transport characteristics of three fluorescent conjugated bile acid analogs in isolated rat hepatocytes and couplets. Hepatology 22:637-647.
16. Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, and Rodriguez M (2007) Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 51:2035-2042.
17. Marion TL, Leslie EM, and Brouwer KL (2007) Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 4:911-918.
18. McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, and Kashuba AD (2006) Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 318:1068-1075.
19. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, and Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-1677.
20. Meijer DKF and Lennernas H (2005) EUFEPS conference on Drug Transporters at Copenhagen: integrative approaches in ADME research. Eur J Pharm Sci 26:130-143.
21. +/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575-1581.
22. Rittweger M and Arasteh K (2007) Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 46:739-756.
23. Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, and Pappa KA (2007) Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 51:560-565.
24. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharmacol Res 19:147-153.
25. Spivey JR, Bronk SF, and Gores GJ (1993) Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes: role of ATP depletion and cytosolic free calcium. J Clin Invest 92:17-24.
26. 2 cells. Mol Pharm 1:49-56.
27. Sulkowski MS, Thomas DL, Chaisson RE, and Moore RD (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80.
28. Swainston Harrison T and Scott LJ (2005) Atazanavir: a review of its use in the management of HIV infection. Drugs 65:2309-2336.
29. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
30. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
31. Williams GC and Sinko PJ (1999) Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 39:211-238.